ITOCO Inc.
TORONTO, ON / ACCESSWIRE / November 18, 2021 / ITOCO INC. (OTC PINK:ITMC) ITOCO is pleased to announce it has selected LATINCHOICE - UNIPESSOAL LDA. in Portugal to Joint Venture as it expands its Nopal Cactus Carbon Capture Program internationally.
The ITOCO Nopal Cactus Carbon Capture Program has been developed with great success in Mexico.
The program captures Carbon from the atmosphere permanently via the Nopal Cactus, while at the same time being a highly beneficial cash crop. Additionally, introducing the Cactus into arid landscapes strategically can help in successfully re-establishing trees, grasses, and other plants to an otherwise barren landscape.
Itoco recently spoke about these initiatives at COP 26, the annual United Nations Climate Change Conference just held at Glasgow, UK.
Europe is aggressively implementing Carbon reduction programs and ITOCO is introducing its unique Carbon Capture initiative as an additional natural source of carbon capture (reduction) that can also service to rehabilitate arid areas of the continent.
The ITOCO Nopal Cactus Program has already been proven with thousands of Hectares under management with the support of the Government of Mexico. Mexico has endorsed the Paris Agreement adopted at the twenty-first session of the Conference of the Parties ("COP") to the United Nation Framework Convention on Climate Change ("UNDCC") and is taking action to mitigate its Green House Gas ("GHG") emissions in accordance with the Land Use Protocol of the United Nations (LULUCF), by 2030.
The ITOCO Program in Mexico has demonstrated Nopal Cactus farming innovations that leverages the cacti's superb adaptation to dry and arid landscapes, which include fixing carbon dioxide at night and closing the spores (stomata) during the day, thus earning producers carbon credits at an accelerated pace in under twelve months.
Nopal Cactus is able to trap up to 30 tons of carbon dioxide per hectare per year.
The Cactus is also able to offer strong vegetative cover against erosion or desertification while being able to tolerate a wide range of temperatures and to thrive in water limited environments. As is characterized by a wide-spreading fibrous roots system allowing it to access surface water and its succulent stems and pads store large quantities of water per hectare. These can be obtained by factory processing and purified for domestic use as acknowledged by the United Nations Food Agriculture Organization.
The Nopal Cactus Carbon Program is an inexpensive option to protect the environment, begin the rehabilitation of land and soil, and obtain these benefits more efficiently than by the extremely difficult talk of planting trees initially Arid areas. In fact, planting the Cactus ultimately allows trees to flourish more quickly. Cactus' period to maturity is much shorter and thus benefits the people by producing fruit, vegetables, flour, fertilizer, animal feed, biomass, biofuel, etc.
LATINCHOICE has been selected for its stellar business development and government relations experience and its network of key partners throughout Europe. Located in Lisbon, Portugal, LATINCHOICE will be responsible for government relations, farmer participation and the application and administration of carbon tax credits.
About ITOCO Inc.
ITOCO's mission is to be a global leader in developing, distributing, and producing Bio Tech related technologies and methodologies in a compliant environmentally friendly manner. ITOCO Inc. trades on the OTC Markets, symbol: ITMC. ITOCO is a 14-year-old publicly quoted specialty Bio Tech development, production and distribution company based in Toronto Canada and Nevada USA. ITOCO seeks to partner with outstanding individuals and companies within this field to joint venture, research, and co-develop Bio Tech related products and technologies to the market.
CONTACT:
Michael Paul, C.E.T.
President & CEO
ITOCO INC
ir@itoco.net
+1-800-805-1521
www.itoco.net
SOURCE: ITOCO Inc.
View source version on accesswire.com:
https://www.accesswire.com/673637/ITOCO-Launches-Its-Nopal-Cactus-Carbon-Capture-Program-in-Portugal-Through-a-Joint-Venture-with-LATINCHOICE-UNIPESSOAL-LDA
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Datavault AI Announces Target to Expand its AI Driven Data Monetization Network to Over 100 Cities Across the Contiguous United States, Starting in the Second Half of 2026 with Corresponding 2027 Revenue Target12.1.2026 14:05:00 CET | Press release
Datavault AI expects to have a fully operational network with over 100 nodes across 33 cities nationwide, generating revenue in the second half of 2026. Target revenue for this project is $400 to $500 million, thereby supporting the $200 million revenue guidance for 2026. With the full deployment of Datavault AI's nodes across 100+ cities throughout the United States, the 2027 revenue target is $2.0 to $3.0 billion for 2027. New York and Philadelphia edge network activation positions Datavault AI to potentially capture a significant share of the insurance and financial sectors, the healthcare industry, and enterprise opportunities. PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 12, 2026 / Datavault AI Inc. (Nasdaq:DVLT), a leader in AI-driven data valuation, monetization, credentialing, and digital engagement technologies, today highlighted the strategic importance of its New York and Philadelphia edge network deployment with Available Infrastructure's SanQtum AI platform. This
OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC12.1.2026 13:00:00 CET | Press release
Successful Delivery of Commissioned ADC Candidate to Advance the Collaboration Between OBI and TegMine TAIPEI, TW / ACCESS Newswire / January 12, 2026 / OBI Pharma (4174.TWO) announced that it has entered into a commercial license agreement with TegMine Therapeutics, Inc. (TegMine), a San Francisco-based biopharma focused on developing antibodies targeting cancer-associated glycans and glycoproteins, for a glycan-targeting ADC. Under the terms of the agreement, OBI is eligible to receive an upfront payment as well as development and commercial milestones. Following product launch, OBI will also receive royalties based on a tiered percentage of annual net sales. While the detailed financial terms are not disclosed in accordance with the confidentiality provisions, the overall deal economics are broadly comparable to those of recent similar licensing transactions in the market. TegMine will obtain the exclusive global rights to develop and commercialize the ADC under the license agreemen
Charlie's Holdings (OTCQB:CHUC) Signs Agreement with IKE Tech to Commercialize Transformational Age-Gated Vapes that Will Address FDA Concerns Related to Youth Access12.1.2026 12:00:00 CET | Press release
SBX Product Line Will Feature First-Ever AI-Powered Blockchain-Based Age-Gating System for Vape Products IKE's patented biometric BLE Bluetooth chip and blockchain-based app will enable Charlie's to ensure that underage individuals will not be able to activate or utilize the Company's age-gated products. The IKE Licensing Agreement provides CHUC with a first mover advantage in youth access prevention (one of the FDA's top priorities) and a three-year exclusivity period for age-gated nicotine analogue products. Charlie's will test market the IKE age-gating system this spring with the Company's popular SBX nicotine analogue product line; simultaneously, Charlie's intends to incorporate the revolutionary technology into its PACHA branded Electronic Nicotine Delivery Systems (ENDS). COSTA MESA, CA / ACCESS Newswire / January 12, 2026 / Charlie's Holdings, Inc. (OTCQB:CHUC) ("Charlie's" or the "Company"), an industry leader in the premium vapor products space, today reported that the Compan
Datavault AI Celebrates Successful Completion of Dream Bowl XIV, Pioneering Blockchain Innovation in Sports Entertainment12.1.2026 12:00:00 CET | Press release
On January 10, 2026, a few dozen of NFL Alumni Greats (click here for a list of participating athletes) live-autographed 100 Footballs (click here to view the autographed NFL Alumni Footballs) and 500 Jerseys (click here to view the autographed NFL Alumni Jerseys); Starting on February 1, 2026, these special, one-time, live-autographed memorabilia items are to be given away by lottery to eligible holders of Dream Bowl Meme Coin I tokens and, following their distribution date (currently set for February 21, 2026), Dream Bowl Meme Coin II tokens and will be tradable on the upcoming International NIL Exchange; $25,000 E-Sports Scholarships Raised by Sponsors were Given to Dream Bowl Madden and Team E-Sports Champions; and 70 Student Star Athletes Showcased their Talent to USFL, NFL and European League Scouts (click here to view the Special Dream Bowl XIV Participants' Jerseys). PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 12, 2026 / Datavault AI Inc. (NASDAQ:DVLT) ("Datavault AI
PromiCell, Inc. presents during JP Morgan's 2026 Healthcare Conference9.1.2026 18:35:00 CET | Press release
MIAMI, FL / ACCESS Newswire / January 9, 2026 / PromiCell, Inc. (the "Company"), a clinical-stage cellular immunotherapy company uniquely positioned to advance potentially curative cell therapies for cancer patients, today announced that the Company's Chief Medical Officer, John Lee, MD, Ph.D., will present interim results of the Company's lead asset PRO CAR - 201A, a STEAP1 directed CAR T cell that is currently in the clinic as a first-in-human phase 1 trial for the treatment of metastatic castration-resistant prostate cancer (mCRPC), at Biotech Showcase 2026 in San Francisco, California on Monday, January 12, 2025 at 11:15 am PST at the Franciscan D (Ballroom Level). About PromiCell, Inc. PromiCell, is a clinical-stage cellular immunotherapy company with product candidates representing highly differentiated and novel CAR T and TCR T platforms to be developed across separate solid and hematologic types of cancer. Our pipeline of innovative products includes STEAP 1 CAR T cells, HA-1 T
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
